Medifast Announces Second Quarter 2026 Financial Results
Business Wire (Mon, 3-Aug 4:05 PM ET)
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026
Business Wire (Mon, 20-Jul 4:05 PM ET)
Medifast Enters a New Era: Introducing Trilivy , a Science-Backed Metabolic Health System
Business Wire (Fri, 17-Jul 8:30 AM ET)
What Science-Backed Subscription Health Programs Measure Differently
Globe Newswire (Thu, 11-Jun 7:00 AM ET)
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
Globe Newswire (Thu, 11-Jun 7:00 AM ET)
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
Business Wire (Tue, 26-May 4:05 PM ET)
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
Globe Newswire (Thu, 21-May 7:00 AM ET)
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
Globe Newswire (Thu, 21-May 7:00 AM ET)
Globe Newswire (Fri, 15-May 1:00 PM ET)
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
Globe Newswire (Fri, 15-May 1:00 PM ET)
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Medifast trades on the NYSE stock market under the symbol MED.
As of August 13, 2026, MED stock price climbed to $11.76 with 9,018 million shares trading.
MED has a beta of 1.60, meaning it tends to be more sensitive to market movements. MED has a correlation of 0.19 to the broad based SPY ETF.
MED has a market cap of $129.25 million. This is considered a Micro Cap stock.
Last quarter Medifast reported $76 million in Revenue and -$.28 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.38.
In the last 3 years, MED traded as high as $93.75 and as low as $9.22.
The top ETF exchange traded funds that MED belongs to (by Net Assets): AVUV, VTI, FNDA, SMLF, VXF.
MED has underperformed the market in the last year with a return of -10.8%, while the SPY ETF gained +22.3%. In the last 3 month period, MED fell short of the market, returning -6.4%, while SPY returned +5.8%. However, in the most recent 2 weeks MED has outperformed the stock market by returning +22.0%, while SPY returned +6.8%.
MED support price is $11.21 and resistance is $11.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MED shares will trade within this expected range on the day.
